Epithalon inhibits tumor growth and expression of HER-2/neu oncogene in breast tumors in transgenic mice characterized by accelerated aging.
Female transgenic FVB mice carrying breast cancer gene HER-2/neu were monthly injected with Vilon or Epithalon (1 microgram subcutaneously for 5 consecutive days) starting from the 2nd month of life. Epithalon markedly inhibited neoplasm development: the maximum size of breast adenocarcinomas was 33% lower than in the control (p < 0.05). The intensity of HER-2/neu mRNA expression in breast tumors of Epithalon-treated mice was 3.7 times lower than in control animals. These results indicate that Epithalon inhibits breast tumor development in transgenic mice, which is probably related to suppression of HER-2/neu expression.
Anisimov
V N
VN
St. Petersburg Institute of Bioregulation and Gerontology, Northwestern Division of the Russian Academy of Medical Sciences, St. Petersburg. aging@mail.ru
Khavinsov
V Kh
VKh
Alimova
I N
IN
Provintsiali
M
M
Manchini
R
R
Francheski
K
K
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism; D000375:Aging / Q000502:physiology*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004151:Dipeptides / Q000627:therapeutic use*; D005260:Female; D015870:Gene Expression; D018734:Genes, erbB-2; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy* / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009842:Oligopeptides / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000378:metabolism; D011897:Random Allocation
D000970:Antineoplastic Agents; D004151:Dipeptides; D009842:Oligopeptides; D012333:RNA, Messenger; C415909:lysylglutamic acid; C421253:alanyl-glutamyl-aspartyl-glycine